Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

NAActive, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Tocilizumab Asprin

"Tocilizumab alone, Asprin alone, Tocilizumab combined with Asprin. Tocilizumab, an IL6R inhibitor, injected once a month at a dose of 4mg/kg in advanced NPC patients.~Asprin,an anticoagulant, taken orally once daily at a dose of 100mg in advanced NPC patients."

OTHER

Placebo

Placebo replaces tocilizumab and asprin in advanced NPC patients.

Trial Locations (1)

226000

Bo You, Nantong

All Listed Sponsors
lead

Affiliated Hospital of Nantong University

OTHER